Clinical trial

Chronic Obstructive Pulmonary Disease (COPD)-Related Outcomes and Costs for Patients on Combination Fluticasone Propionate-Salmeterol Xinafoate 250/50mcg Versus Anticholinergics in a COPD-Comorbid Depression/Anxiety Population

NCT01337336

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention fluticasone propionate/salmeterol xinafoate Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Anticholinergics Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Chronic Obstructive Pulmonary Disease (COPD)-Related Outcomes and Costs for Patients on Combination Fluticasone Propionate-Salmeterol Xinafoate 250/50mcg Versus Anticholinergics in a COPD-Comorbid Depression/Anxiety Population

Design: OBSERVATIONAL · Status: COMPLETED · Phase: Not specified

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeOBSERVATIONAL

Start date2010-10-01

PhaseN/A

Conditions

Pulmonary Disease, Chronic Obstructiveunresolved

Interventions

fluticasone propionate/salmeterol xinafoateDRUG

AnticholinergicsDRUG

Sponsors & collaborators

GlaxoSmithKlinelead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01337336 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.